Optimized quantities of GDNF overexpressed by engineered astrocytes are critical for protection of neuroblastoma cells against 6-OHDA toxicity

Journal of Molecular Neuroscience

Volumn 46, Issue 3, 2012, Pages 654-665

  Safi, Roya ^a   Gardaneh, Mossa ^a,b   Panahi, Yasin ^a   Maghsoudi, Nader ^b   Zaefizadeh, Mohammad ^a   Gharib, Ehsan ^a  

^a NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Astrocytes; Dopaminergic; GDNF; Lentiviral vectors; Lentivirus; Neuroprotection; Parkinson's disease

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; ASTROCYTE; CELL ENGINEERING; CELL STRUCTURE; CELL SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; DILUTION; GENE CONSTRUCT; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; LENTIVIRINAE; MOUSE; NERVE CELL GROWTH; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN SECRETION; QUANTITATIVE ANALYSIS;

ANIMALS; APOPTOSIS; ASTROCYTES; ASTROCYTOMA; CELL DEATH; CELL LINE, TUMOR; CYTOPROTECTION; FEASIBILITY STUDIES; GENETIC ENGINEERING; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HEK293 CELLS; HUMANS; MICE; MICE, INBRED C57BL; NEUROBLASTOMA; OXIDOPAMINE; PARKINSON DISEASE; SYMPATHOLYTICS;

LENTIVIRUS; PARKINSONIA;

EID: 84859157176     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-011-9654-8     Document Type: Article

References (69)

1. Airaksinen MS, SaarmaM(2002) The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3:383-394 (Pubitemid 135706635)
2. Akerud P, Canals JM, Snyder EY, Arenas E (2001) Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J Neurosci 21:8108-8118 (Pubitemid 32952767)
3. Arai K, Lo EH (2010) Astrocytes protect oligodendrocyte precursor cells via MEK/ERK and PI3K/Akt signaling. J Neurosci Res 88:758-763
4. Björklund A, Rosenblad C, Winkler C, Kirik D (1997) Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 4:186-200 (Pubitemid 27465509)
5. Björklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ (2000) Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 886:82-98
6. Bohn MC (2004) Motoneurons crave glial cell line-derived neurotrophic factor. Exp Neurol 190:263-275
7. Böhr M (2004) Neuroprotection: models, mechanisms and therapies. Wiley, Weinheim
8. Brown DR (1999) Neurons depend on astrocytes in a coculture system for protection from glutamate toxicity. Mol Cell Neurosci 13:379-389
9. Brundin P (2002) GDNF treatment inParkinson's disease: time for controlled clinical trials? Brain 125:2149-2151
10. Capowski EE, Schneider BL, Ebert AD (2007) Lentiviral vectormediated genetic modification of human neural progenitor cells for ex vivo gene therapy. J Neurosci Methods 163:338-349 (Pubitemid 46874594)
11. Choi-Lundberg DL, Bohn MC (1995) Ontogeny and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat. Brain Res Dev Brain Res 85:80-88
12. Cunningham LA, Su C (2002) Astrocyte delivery of glial cell linederived neurotrophic factor in a mouse model of Parkinson's disease. Exp Neurol 174:230-242 (Pubitemid 34295786)
13. Deierborg T, Soulet D, Roybon L, Hall V, Brundin P (2008) Emerging restorative treatments for Parkinson's disease. Progress Neurobiol 85:407-432
14. Dhandapani KM, Hadman M, De Sevilla L, Wade MF, Mahesh VB, Brann DW (2003) Astrocyte protection of neurons: role of transforming growth factor-beta signaling via a c-Jun-AP-1 protective pathway. J Biol Chem 278:43329-43339 (Pubitemid 37345954)
15. Ding J, Yu JZ, Li QY, Wang X, Lu CZ, Xiao BG (2009) Rho kinase inhibitor Fasudil induces neuroprotection and neurogenesis partially through astrocyte-derived G-CSF. Brain Behav Immun 23:1083-1088
16. Dringen R, Hirrlinger J (2003) Glutathione pathways inthe brain. Biol Chem 348:505-516
17. Duan D, Yang H, Zhang J, Zhang J, Xu Q (2005) Long-term restoration of nigrostriatal system function by implanting GDNF genetically modified fibroblasts in a rat model of Parkinson's disease. Exp Brain Res 161:316-324 (Pubitemid 40379372)
18. Ebert AD, Barber AE, Heins BM, Svendsen CN (2010) Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease. Exp Neurol 224:155-162
19. Ericson C, Georgievska B, Lundberg C (2005) Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease. Eur J Neurosci 22:2755-2764 (Pubitemid 41811272)
20. Eslamboli A, Georgievska B, Ridley RM et al (2005) Continuous lowlevel glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 25:769-777 (Pubitemid 40170991)
21. Galan-Rodriguez B, del-Marco A, Flores JA, Ramiro-Fuentes S, Gonzalez-Aparicio R, Tunez I, Tasset I, Fernandez-Espejo E (2008) Grafts of extra-adrenal chromaffin cells as aggregates show better survival rate and regenerative effects on parkinsonian rats than dispersed cell grafts. Neurobiol Dis 29:529-542
22. Gardaneh M, Gholami M, Maghsoudi N (2011) Synergy between glutathione peroxidase-1 and astrocytic growth factors suppresses free radical generation and protects dopaminergic neurons against 6-Hydroxydopamine. Rejuven Res 14 (2):195-204
23. Georgievska B, Kirik D, Bjorklund A (2002) Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by longlasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 177:461-474 (Pubitemid 35366135)
24. Gill SS, Patel NK, Hotton GR et al (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9:589-595 (Pubitemid 36597106)
25. Hirsch EC, Faucheux B, Damier P, Mouatt-Prigent A, Agid Y (1997) Neuronal vulnerability inParkinson's disease. J Neural Transm Suppl 50:79-88
26. Hong M, Mukhida K, Mendez I (2008) GDNF therapy for Parkinson's disease. Expert Rev Neurother 8:1125-1139 (Pubitemid 351962079)
27. Horita Y, Honmou O, Harada K, Houkin K, Hamada H, Kocsis JD (2006) Intravenous administration of glial cell line-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in the adult rat. J Neurosci Res 84:1495-1504 (Pubitemid 44683142)
28. Kaddis FG, Zawada WM, Schaack J, Freed CR (1996) Conditioned medium from aged monkey fibroblasts stably expressing GDNF and BDNF improves survival of embryonic dopamine neurons in vitro. Cell Tissue Res 286:241-247 (Pubitemid 26383671)
29. Klein SM, Behrstock S, McHugh J, Hoffmann K, Wallace K, Suzuki M, Aebischer P, Svendsen CN (2005) GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther 16:509-521 (Pubitemid 40647148)
30. Kobayashi T, Ahlenius H, Thored P, Kobayashi R, Kokaia Z, Lindvall O (2006) Intracerebral infusion of glial cell line-derived neurotrophic factor promotes striatal neurogenesis after stroke in adult rats. Stroke 37:2361-2367 (Pubitemid 44337184)
31. Kordower JH, Emborg ME, Bloch J et al (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290:767-773
32. Lang AE, Obeso JA (2004) Challenges inParkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 3:309-316 (Pubitemid 38510202)
33. Lang AE, Gill S, Patel NK et al (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59:459-466 (Pubitemid 43358066)
34. Lin LF, Doherty DH, Lile JD, Bektesh S (1993) Collins F(2010) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132 (Pubitemid 23186789)
35. Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS (2005) Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 11:703-704 (Pubitemid 41021193)
36. Mandel RJ, Burger C, Snyder RO (2008) Viral vectors for invivo gene transfer in Parkinson's disease: properties and clinical grade production. Exp Neurol 209:58-71
37. Matsushita N, Fujita Y, Tanaka M, Nagatsu T, Kiuchi K (1997) Cloning and structural organization of the gene encoding the mouse glial cell line-derived neurotrophic factor. GDNF Gene 203:149-157 (Pubitemid 27522125)
38. McBride JL, During MJ, Wuu J, Chen EY, Leurgans SE, Kordower JH (2003) Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol 181:213-223 (Pubitemid 36629242)
39. McBride JL, Ramaswamy S, Gasmi M, Bartus RT, Herzog CD, Brandon EP, Zhou L, Pitzer MR, Berry-Kravis EM, Kordower JH (2006) Viral delivery of glial cell line-derived neurotrophic factorimproves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 103:9345-9350 (Pubitemid 43902579)
40. Mena MA, Davila V, Sulzer D (2002) Neurotrophic effects of LDOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem 69:1398-1408 (Pubitemid 27406940)
41. Mohajeri MH, Figlewicz DA, Bohn MC (1999) Intramuscular grafts of myoblasts genetically modified to secrete glial cell linederived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis. Hum Gene Ther 10:1853-1866 (Pubitemid 29357691)
42. Morrison PF, Lonser RR, Oldfield EH (2007) Convective delivery of glial cell line-derived neurotrophic factor in the human putamen. J Neurosurg 107:74-83 (Pubitemid 47026475)
43. Nakao N, Yokote H, Nakai K, Itakura T (2000) Promotion of survival and regeneration of nigral dopamine neurons in a rat model of Parkinson's disease after implantation of embryonal carcinomaderived neurons genetically engineered to produce glial cell linederived neurotrophic factor. J Neurosurg 92:659-670 (Pubitemid 30180673)
44. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, Lozano AM, Penn RD, Simpson RK Jr, Stacy M, Wooten GF (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60:69-73 (Pubitemid 36070646)
45. Parsadanian A, Pan Y, Li W, Myckatyn TM, Brakefield D (2006) Astrocyte-derived transgene GDNF promotes complete and longterm survival of adult facial motoneurons following avulsion and differentially regulates the expression of transcription factors of AP-1 and ATF/CREB families. Exp Neurol 200:26-37 (Pubitemid 44080745)
46. Patel NK, Gill SS (2007) GDNF delivery for Parkinson's disease. Acta Neurochir Suppl 97:135-154
47. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS (2005) Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 57:298-302 (Pubitemid 40179870)
48. Pertusa M, Garcia-Matas S, Mammeri H, Adell A, Rodrigo T, Mallet J, Cristofol R, Sarkis C, Sanfeliu C (2007) Expression of GDNF transgene in astrocytes improves cognitive deficits in aged rats. Neurobiol Aging 29:1366-1379
49. Pluta K, Luce ML, Bao L, Agha-Mohammadi S, Reiser J (2005) Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters. J Gene Med 7:803-817 (Pubitemid 40872866)
50. Ponce S, Orive G, Gascón AR, Hernández RM, Pedraz JL (2005) Microcapsules prepared with different biomaterials to immobilize GDNF secreting 3T3 fibroblasts. Int J Pharm 293:1-10 (Pubitemid 40381075)
51. Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson's disease. J Neural Transm Park Dis Dement Sect 38:277-301
52. Rosenblad C, Georgievska B, Kirik D (2003) Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur J Neurosci 17:260-270 (Pubitemid 36459505)
53. Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, Gage FH, Glass CK (2009) A Nurr1/CoREST pathway inmicroglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137:47-59
54. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor
55. Sandhu JK, Gardaneh M, Iwasiow R, Lanthier P, Gangaraju S, Ribecco-Lutkiewicz M, Tremblay R, Kiuchi K, Sikorska M (2009) Astrocyte-secreted GDNF and glutathione antioxidant system protect neurons against 6OHDA cytotoxicity. Neurobiol Dis 33:405-414
56. Sariola H, Saarma M (2003) Novel functions and signalling pathways for GDNF. J Cell Sci 116:3855-3862 (Pubitemid 37279301)
57. Schneider B, Zufferey R, Aebischer P (2008) Viral vectors, animal models and new therapies for Parkinson's disease. Parkinsonism Relat Disord 2:S169-S171
58. Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW (2006) Crossroads inGDNF therapy for Parkinson's disease. Mov Disord 21:136-141
59. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B (2005) Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102:216-222 (Pubitemid 43194069)
60. Slevin JT, Gash DM, Smith CD, Gerhardt GA, Kryscio R, Chebrolu H, Walton A, Wagner R, Young AB (2007) Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg 106:614-620 (Pubitemid 46536457)
61. Wallén-Mackenzie Å, de Urquiza AM, Petersson S, Rodriguez FJ, Friling S, Wagner J, Ordentlich P, Lengqvist J, Heyman RA, Arenas A, Perlmann T (2003) Nurr1-RXR heterodimers mediate RXR ligand-induced signaling in neuronal cells. Genes Dev 17:3036-3047 (Pubitemid 38040768)
62. Wang L, Muramatsu S, Lu Y, Ikeguchi K, Fujimoto K, Okada T, Mizukami H, Hanazono Y, Kume A, Urano F, Ichinose H, Nagatsu T, Nakano I, Ozawa K (2002) Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther 9:381-389 (Pubitemid 34414036)
63. Yacoubian TA, Standaert DG (2009) Targets for neuroprotection inParkinson's disease. Biochim Biophys Acta 1792:676-687
64. Yang D, Peng C, Li X, Fan X, Li L, Ming M, Chen S, Le W (2008) Pitx3-transfected astrocytes secrete brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor and protect dopamine neurons in mesencephalon cultures. J Neurosci Res 86:3393-3400
65. Yasuhara T, Shingo T, Date I (2007) Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease. Acta Med Okayama 61:51-56 (Pubitemid 46798852)
66. Yoshida M, Saito H, Katsuki H (1995) Neurotrophic effects of conditioned media of astrocytes isolated from different brain regions on hippocampal and cortical neurons. Experientia 51:133-136
67. Zhao Z, Alam S, Oppenheim RW, Prevette DM, Evenson A, Parsadanian A (2004) Overexpression of glial cell line-derived neurotrophic factor in the CNS rescues motoneurons from programmed cell death and promotes their long-term survival following axotomy. Expt Neurol 190:356-372 (Pubitemid 39504992)
68. Zhu ZH, Yang R, Fu X, Wang YQ, Wu GC (2006) Astrocyteconditioned medium protecting hippocampal neurons in primary cultures against corticosterone- induced damages via PI3-K/Akt signal pathway. Brain Res 1114:1-10 (Pubitemid 44414781)
69. Ziv I, Barzilai A, Offen D, Nardi N, Melamed E (1997) Nigrostriatal neuronal death inParkinson's disease-a passive or an active genetically- controlled process? J Neural Transm Suppl 49:69-76 (Pubitemid 27351474)